BioPorto

Share Issue/Capital Change • Aug 23, 2012

The Board of BioPorto A/S today has decided to carry out a cash issue, private
placement.

The capital increase will be effected by means of the Board’s exercise of the
authorization stipulated in Article 16b of the Company’s Articles of
Association, whereby the Board is authorized until 17th of April 2017 to
increase the share capital on one or more occasions by issuing new shares up to
the nominal value of DKK 80,000,000.

The capital increase takes the form of a cash issue for a limited group of
investors without a pre-emptive right for the Company’s previous shareholders.
The public offering is 1,500,000 new shares at a price of DKK 3.00 each,
equivalent to the nominal value of DKK 4,500,000.

The new shares equate to 3,3% of BioPorto’s registered share capital before the
capital increase, thus making the cash issue exempt from the obligation to
publish a prospectus.

The same rights apply to newly subscribed shares as to the existing shares. The
subscription price is 250, which equates to DKK 7.50 per share at a nominal
value of DKK 3.00. The subscription price exceeds the weighted average price of
the shares over the past ten trading days.

The subscription period starts today and ends on September 14, 2012. The Board
of Directors shall have discretion whether subscription of shares is accepted
in whole or in part by the company. The Board of Directors may also decide that
one or more subscription commitments should be reduced or terminated, eg due to
changes in market conditions. In the event of oversubscription, the board will
make a decision on the allocation of shares.

The company has received binding acceptance of subscription of the full amount
of the increase from a professional investor.

The capital increase will be registered with the Danish Commerce and Companies
Agency as soon as the amount of the increase has been realized, which is
expected to be no later than September 21, 2012.

The company will arrange for the inclusion of the new shares for trading on
NASDAQ OMX Copenhagen; this is anticipated by the end of September 2012.

Proceeds and use of proceeds

The total proceeds from the share issuance amount to DKK 11.250.000, from which
transaction costs - budgeted at DKK 600.000 - will be deducted.

The share issuance will re-establish the company’s equity capital, and
proceeds will be used to the daily operation of the company and the
FDA-studies. Future financing of the daily operation of the company and debt
obligations will be secured by increasing operating income primary from The
NGAL Test ™.

For further information, please contact:

Frank Harder, CFO

Christina Thomsen, Investor Relations

Telephone +45 4529 0000, e-mail investor@bioporto.com

     For further information, please contact:

     Frank Harder, CFO

     Christina Thomsen, Investor Relations

     Telephone +45 4529 0000, e-mail investor@bioporto.com